Background An estimated 2· 5 billion people are at risk of dengue. Incidence of dengue is
especially high in resource-constrained countries, where control relies mainly on …

Since the introduction of the cost-effectiveness acceptability curve (CEAC) in 1994, its use
as a method to describe uncertainty around incremental cost-effectiveness ratios (ICERs) …

Objective: Economic evaluations commonly accompany trials of new treatments or
interventions; however, regression methods and their corresponding advantages for the …

Decision making in health technology assessment (HTA) involves multiple criteria (clinical
outcomes vs. cost) and risk (criteria measured with estimation error). A survey conducted …

Background To demonstrate the use of risk-benefit analysis for comparing multiple
competing interventions in the absence of randomized trials, we applied this approach to the …

Cost-effectiveness analysis is becoming an increasingly important tool for decision making
in the health systems. Cost-Effectiveness of Medical Treatments formulates the cost …

This paper deals with the decision problem of choosing an optimal medical treatment,
among M possible candidates, when the states of nature are the net benefit of the …

Dealing with randomness is a crucial aspect that cost-effectiveness analysis (CEA) tools
need to address, but existing stochastic CEA tools have rarely examined risk and return from …

We present an approach to rank order new programs in ways that accommodate uncertainty
of different outcomes occurring, on the basis of the size and nature ('bad'or 'good') of those …

One of the responsibilities of the health care sector regulator is to decide which health
technologies (drugs, procedures, diagnostic tests, etc.) should be financed using public …